SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:gup.ub.gu.se/316062"
 

Sökning: id:"swepub:oai:gup.ub.gu.se/316062" > Formation, Signalin...

Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators-What is the Evidence so far?

Schebb, N. H. (författare)
Kuehn, H. (författare)
Kahnt, A. S. (författare)
visa fler...
Rund, K. M. (författare)
O'Donnell, V. B. (författare)
Flamand, N. (författare)
Peters-Golden, M. (författare)
Jakobsson, P. J. (författare)
Karolinska Institutet
Weylandt, K. H. (författare)
Rohwer, N. (författare)
Murphy, R. C. (författare)
Geisslinger, G. (författare)
FitzGerald, G. A. (författare)
Hanson, J. (författare)
Dahlgren, Claes, 1949 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research
Alnouri, M. W. (författare)
Offermanns, S. (författare)
Steinhilber, D. (författare)
visa färre...
 (creator_code:org_t)
2022-03-02
2022
Engelska.
Ingår i: Frontiers in Pharmacology. - : Frontiers Media SA. - 1663-9812. ; 13
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Formation of specialized pro-resolving lipid mediators (SPMs) such as lipoxins or resolvins usually involves arachidonic acid 5-lipoxygenase (5-LO, ALOX5) and different types of arachidonic acid 12- and 15-lipoxygenating paralogues (15-LO1, ALOX15; 15-LO2, ALOX15B; 12-LO, ALOX12). Typically, SPMs are thought to be formed via consecutive steps of oxidation of polyenoic fatty acids such as arachidonic acid, eicosapentaenoic acid or docosahexaenoic acid. One hallmark of SPM formation is that reported levels of these lipid mediators are much lower than typical pro-inflammatory mediators including the monohydroxylated fatty acid derivatives (e.g., 5-HETE), leukotrienes or certain cyclooxygenase-derived prostaglandins. Thus, reliable detection and quantification of these metabolites is challenging. This paper is aimed at critically evaluating i) the proposed biosynthetic pathways of SPM formation, ii) the current knowledge on SPM receptors and their signaling cascades and iii) the analytical methods used to quantify these pro-resolving mediators in the context of their instability and their low concentrations. Based on current literature it can be concluded that i) there is at most, a low biosynthetic capacity for SPMs in human leukocytes. ii) The identity and the signaling of the proposed G-protein-coupled SPM receptors have not been supported by studies in knock-out mice and remain to be validated. iii) In humans, SPM levels were neither related to dietary supplementation with their omega-3 polyunsaturated fatty acid precursors nor were they formed during the resolution phase of an evoked inflammatory response. iv) The reported low SPM levels cannot be reliably quantified by means of the most commonly reported methodology. Overall, these questions regarding formation, signaling and occurrence of SPMs challenge their role as endogenous mediators of the resolution of inflammation.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)

Nyckelord

lipoxygenase
SPM
lipoxin
resolvin
resolution of inflammation
leukotriene
FPR
LC-MS-based lipid mediator analysis
platelet-type 12-lipoxygenase
5-lipoxygenase knockout mice
formyl
peptide receptors
lipoxin a(4)
arachidonic-acid
fatty-acid
positional specificity
15-epi-lipoxin a(4)
international union
antiinflammatory properties
Pharmacology & Pharmacy

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy